CorMedix Inc
SWB:19KA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
CorMedix Inc
SWB:19KA
|
US |
|
R
|
Rane (Madras) Ltd
NSE:RML
|
IN |
|
D
|
Derichebourg SA
XBER:PNU
|
FR |
|
Hong Leong Asia Ltd
F:HOM
|
SG |
|
Aurea SA
F:94P
|
FR |
|
Singapore Post Ltd
SGX:S08
|
SG |
|
B
|
Banca IFIS SpA
SWB:0I6
|
IT |
|
S
|
secunet Security Networks AG
XHAM:YSN
|
DE |
|
Aura Biosciences Inc
NASDAQ:AURA
|
US |
|
Mphasis Ltd
BSE:526299
|
IN |
|
Mink Therapeutics Inc
NASDAQ:INKT
|
US |
Wall St Price Targets
19KA Price Targets Summary
CorMedix Inc
According to Wall Street analysts, the average 1-year price target for 19KA is 13.333 EUR with a low forecast of 11.291 EUR and a high forecast of 17.156 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 19KA's stock price target?
Price Target
13.333
EUR
According to Wall Street analysts, the average 1-year price target for 19KA is 13.333 EUR with a low forecast of 11.291 EUR and a high forecast of 17.156 EUR.
What is the Revenue forecast for CorMedix Inc?
Projected CAGR
8%
The compound annual growth rate for Revenue over the next 8 years is 8%.
What is the Gross Profit forecast for CorMedix Inc?
Projected CAGR
8%
The compound annual growth rate for Gross Profit over the next 5 years is 8%.
What is the Operating Income forecast for CorMedix Inc?
Projected CAGR
6%
The compound annual growth rate for Operating Income over the next 8 years is 6%.
What is the Pre-Tax Income forecast for CorMedix Inc?
Projected CAGR
-28%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -28%.
What is the Net Income forecast for CorMedix Inc?
Projected CAGR
-36%
The compound annual growth rate for Net Income over the next 3 years is -36%.
